These ASX shares are actively fighting coronavirus

As the battle against coronavirus becomes a war, we take a look at 2 ASX shares actively involved in the fight against the virus.

| More on:
small figure representing ASX shares with cape and shield fighting coronavirus

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus situation in Victoria seems to be worsening by the day. With a nightly curfew and even tighter lockdown laws taking effect at midnight tonight, the state appears to be under siege. Some ASX shares are actively playing a part in the fight against the virus and the treatment of patients. As the battle against the pandemic increasingly becomes a war, we take a look at two ASX shares involved in the fight against COVID-19. 

2 ASX shares fighting against coronavirus

Mesoblast Limited (ASX: MSB)

Mesoblast is a regenerative medicine company seeking to provide treatments for inflammatory illnesses. The company has a portfolio of phase 3 product candidates including remestemcel-L, which is being trialed in the treatment of severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection. 

Interim analysis of the phase 3 trial of remestemcel-L in COVID-19 patients is set for early September. The trial's first 90 patients will complete 30-day follow ups in August. After this, the Data Safety Monitoring Board will assess the interim data and determine whether the trial should proceed or stop early. There are currently no approved treatments for ARDS in COVID-19 patients, so if Mesoblast's treatment is approved it would be a first. With ARDS the primary cause of death in COVID-19 patients, demand for an effective treatment is high. 

Remestemcel-L was originally developed to treat acute graft versus host disease (GVHD). An application for the use of the treatment in children with the disease is being assessed by the United States FDA (Food and Drug Administration). If approved, Mesoblast plans to launch in the US this year with product inventory in place. 

Fisher & Paykel Healthcare Corp Ltd (ASX: FPH

Fisher & Paykel Healthcare manufactures products used in respiratory and acute care. In the respiratory market since 1971, Fisher & Paykel Healthcare's products are now being used in the treatment of coronavirus patients. The company's respiratory humidifiers and consumables are directly involved in COVID-19 treatment. Fisher & Paykel has seen an increase in demand globally since the start of the pandemic and has ramped up production accordingly. 

A weaker New Zealand dollar also contributed to Fisher & Paykel's strong result for the year ended 31 March 2020. Operating revenue increased 18% over the previous year to $1.26 billion. This increase was driven by demand for products to treat COVID-19 patients and strong hospital hardware sales throughout the year. Revenue grew 25% in the hospital group, which includes respiratory and acute care products. Sales of consumables were up 23% over the previous year. This added up to a 37% increase in net profit after tax, with a final dividend of 15.5 cents per share declared. 

Foolish takeaway 

These two ASX shares provide products and treatments used to combat the coronavirus in those afflicted. Until a vaccine is found, these ASX shares should see steady demand. 

Motley Fool contributor Kate O'Brien has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »